Trial Profile
A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CANTATA-SU
- Sponsors Janssen Research & Development; Johnson & Johnson
- 08 Jul 2022 Results of post-hoc analysis of five studies (NCT01081834, NCT01106677, NCT00968812, NCT01032629 & NCT01989754) assessing efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method, published in the Diabetologia.
- 15 Sep 2017 Results of a post-hoc analysis assessing the effects of Canagliflozin versus Glimepiride on select adipokines (n=200), inflammatory markers, and chemokines presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 01 Dec 2016 Pooled analysis of 7 studies including this one and results of substudy of the CANVAS trial (n=432) were published in the Diabetes Therapy.